Balance After Cancer - Is it Even Possible? (Part 1 of 2)

Patient Info: Anonymized, Male, 70+ | Stage III

At age 72, the patient was 5 years beyond lung surgery, breathing normally with one lung and described as in remission. A separate 2-year history of prostate cancer was asymptomatic and also described as in remission.

Many Hats of Caregiving (Part 3 of 3)

Patient Info: Anonymized, Male | Stage III

Carla’s father was described as having survived Stage III lung cancer and being in remission; he was also in remission from a separate early-stage prostate cancer.

Stage III KRAS Lung Cancer: Bill's Survivor Story

Patient Info: Bill Morris, Male | Stage III

Biomarkers: KRAS

After multimodal treatment, Bill had remained actively cancer-free for more than 3 years and used his experience to support other patients.

Stage III ALK Non-Small Cell Lung Cancer: Michelle's Patient Story

Patient Info: Michelle Bos-Lun, Female | Stage III

Biomarkers: ALK-positive

Stage IIIB ALK-positive lung cancer responding to Lorbrena/lorlatinib, with cough improvement within days and first scan showing nearly 50% tumor reduction.

GO2 FoundationRead more →

Stage III EGFR Non-Small Cell Lung Cancer: Lauren's Survivor Story

Patient Info: Lauren, Female, Under 40 | Stage III

Biomarkers: EGFR mutation

No evidence of cancer on 1-year scan after fertility preservation, chemotherapy, radiation, and removal of half the left lung for Stage III EGFR-mutated lung cancer.

Lung Cancer Research FoundationRead more →

Stage III ROS1 Non-Small Cell Lung Cancer: Wendy's Survivor Story

Patient Info: Wendy, Female | Stage III

Biomarkers: ROS1-positive / ROS1-rearranged

Completed chemoradiation, surgery, and post-surgery radiation for Stage III ROS1-positive NSCLC by January 2017 and later shared a long-term survivor/advocacy story; no explicit NED statement is given.

Lung Cancer Research FoundationRead more →

Stage III Lung Adenocarcinoma: Becky's Survivor Story

Patient Info: Becky Manning, Female, 40s | Stage III

After surgery, chemotherapy and 8 months of nivolumab on a clinical trial, Becky was no longer on active treatment, had no evidence of disease, felt well, and returned to MSK every 6 months for follow-up.

Memorial Sloan KetteringRead more →

Stage IIIB lung cancer: heart inflammation from durvalumab immunotherapy, mistaken at first for tumor spreading to the heart

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: No actionable driver mutations identified; PD-L1 tumor proportion score <1%

She recovered cardiac function after treatment for durvalumab-associated myocarditis and remained without lung-cancer relapse or cardiac decline for more than 4 years, with no additional anticancer therapy.

PubMed CentralRead more →

Stage III Lung Adenocarcinoma: Heidi's Survivor Story

Patient Info: Heidi Nafman-Onda, Female, 50s | Stage III

Heidi described living 3 years after a Stage III lung adenocarcinoma diagnosis with a high quality of life and became a lung cancer awareness advocate through The White Ribbon Project.

The Patient StoryRead more →

Long-term complete response to targeted therapy for relapsed lung cancer with an EGFR mutation

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: EGFR mutation

Her three most recent scans showed a complete response, and nearly 4 years after relapse she remained free of tumor progression while continuing targeted therapy.

PubMed CentralRead more →

Stage III Lung Cancer: Bonnie's Patient Story

Patient Info: Bonnie Ulrich, Female, 40s | Stage III

Biomarkers: CA-125 elevated during 2019 workup; no lung cancer driver biomarker reported

After surgery-only Stage I lung cancer and 13 years in remission, Bonnie was later diagnosed with Stage III lung cancer in 2019; the later treatment regimen is not reported.

The Patient StoryRead more →

Pierre Onda: The Caregiver & His Fight for Empathy

Patient Info: Heidi Onda, Female | Stage III

Heidi Onda was diagnosed with Stage III primary lung cancer, and the story focuses on Pierre Onda's caregiver experience and their creation of The White Ribbon Project rather than a detailed treatment course or final disease status.

The Patient StoryRead more →

Stage III Non-Small Cell Lung Cancer: Heidi's Survivor Story

Patient Info: Heidi N., Female, 50s | Stage III

Biomarkers: No targetable mutation identified

As of June 2026, Heidi was featured as a lung cancer advocate after treatment for inoperable Stage IIIA NSCLC; scans through January 2021 had shown no evidence of disease.

The Patient StoryRead more →

Stage III Lung Cancer: Peter's Survivor Story

Patient Info: Peter, Male, 70+ | Stage III

As of May 2026, Peter said his left-lung mass had gone after radiotherapy with chemotherapy and that he had returned to normal activities.

YouTube (AR search)Read more →

Stage III Non-Small Cell Lung Cancer: Susie's Survivor Story

Patient Info: Susie, Female | Stage III

As of May 2026, Susie described completed surgery, chemotherapy, and radiotherapy for Stage III non-small cell lung cancer and was advocating for smoke-free legislation; no NED status was stated.

Cancer Research UKRead more →

Stage III lung cancer treatment complicated by immune-related lung inflammation

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative

Mediastinal lymph nodes later enlarged despite additional systemic treatment, prompting radiation and further therapy.

PubMed CentralRead more →

Stage IIIA lung adenocarcinoma: major pathological response after neoadjuvant immunochemotherapy, complicated by DILI/TEN

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: No lung molecular biomarkers reported

At 23 months after thoracoscopic left upper lobectomy, he was clinically stable with no evidence of tumor recurrence; severe postoperative DILI/TEN had improved after stopping the offending drug and intensive supportive treatment.

PubMed CentralRead more →

Stage III EGFR Lung Cancer: Roxanne's Patient Story

Patient Info: Roxanne, Female, 40s | Stage III

Biomarkers: EGFR mutation

Roxanne had Stage III EGFR-mutated lung cancer after surgery found mediastinal lymph-node involvement. As of March 2026, she was living with the long-term effects of surgery, chemotherapy, radiation, and ongoing EGFR-targeted therapy, while also managing the emotional and financial burden of cancer as a single parent.

The Patient StoryRead more →

Targeted therapy made Stage III ALK-positive lung cancer operable

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ALK-positive; PD-L1 high

Surgery found no residual cancer, and follow-up scans showed no recurrence through 15 months.

PubMed CentralRead more →

Stage IIIA KRAS/STK11/TP53-mutated lung adenocarcinoma: fatal pembrolizumab-induced myocarditis after adjuvant therapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Ki-67 20-25%; PD-L1 expression 10%; KRAS exon 2 mutation; STK11 mutation; TP53 mutation

As of December 2025, he had died after 15 days of hospitalization from sepsis and multi-organ failure following severe pembrolizumab-induced myocarditis after adjuvant treatment for resected Stage IIIA lung adenocarcinoma.

PubMed CentralRead more →

Stage IIIB RET-fusion lung adenocarcinoma: disease-free after pralsetinib, surgery and maintenance therapy

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: RET exon 12 fusion. Lung-origin markers were present

After neoadjuvant pralsetinib, surgery showed pathological complete response with negative lymph nodes. As of 16 April 2025, surveillance imaging showed no recurrence while he remained on pralsetinib 300 mg once daily.

PubMed CentralRead more →

Stage IIIA lung adenocarcinoma: complete metabolic remission after chemoradiotherapy, complicated by radiation esophagitis

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: No molecular biomarkers reported

The primary lung lesion achieved complete metabolic remission after concurrent chemoradiotherapy, and radiation esophagitis/stricture improved with conservative management until swallowing returned to a normal diet by 16 months.

PubMed CentralRead more →

Stage III Lung Cancer Treatment Complicated by Adult T-Cell Leukemia/Lymphoma

Patient Info: Anonymized, male, 70+ | Stage III

The lung cancer had a partial response after chemoradiotherapy, and no lung-cancer progression was observed after durvalumab was stopped during subsequent follow-up.

PubMed CentralRead more →

Stage IIIA KRAS p.G12V lung adenocarcinoma: pathologic complete response after chemoimmunotherapy and surgery

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: KRAS p.G12V mutation; PD-L1 0% tumor-cell staining; <1% tumor-associated inflammatory-cell staining; no EGFR, ALK, or ROS1 driver mutation reported

Pathology after lobectomy showed a pathologic complete response, and surveillance imaging 12 months later showed no evidence of disease recurrence.

PubMed CentralRead more →